February 11, 2010

TCF7L2, What this Very Common Type 2 Diabetes Gene Does

Many of you have been sold a bill of goods about how you "caused your diabetes" with unhealthy lifestyle choices. The media are full of articles telling us that diabetes is caused by obesity and failure to exercise which cause insulin resistance. You might have been told that while people with Type 1 Diabetes don't secrete insulin, people with Type 2 Diabetes secrete too much insulin. Though doctors repeat this misinformation, it turns out not to be true.

High quality research suggests very strongly that most Type 2 Diabetes results from genetic damage. This damage may be inherited or it may be caused by environmental pollutants like arsenic, PCBs, pesticides and popular prescription drugs. The environment of the womb can also permanently alter the expression of certain genes in ways that promote the development of Type 2 Diabetes.

Since the research has made it clear that most Type 2 is inherited, scientists have been using the new, cheap tools for studying the genome, to search for the gene variants that are common among people with Type 2 diabetes and absent in the rest of the population.

The single most common Type 2 Diabetes gene they've found in populations of people with Western European heritages is a variant of TCF7L2. A study published in this month's edition of the journal Diabetes sheds much light on why this gene is so closely associated with (i.e. causes) Type 2 Diabetes. You can find the study here:

TCF7L2 Variant rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action
Dennis T. Villareal et al. Diabetes Diabetes February 2010 vol. 59 no. 2 479-485, doi: 10.2337/db09-1169

First off, ignore the article's title. As is becoming more and more common, the titles of research studies are being slanted to appeal to whatever the fashionable belief of the year might be in diabetes research. And as is also common, that fashionable belief is heavily influenced by the mechanisms used by whatever new drugs are being peddled by Big Pharma. Since right now incretin drugs are the hottest (i.e. most expensive) new drugs, the researchers pitched this article as if it was a study documenting the effect of the defective TCF7L2 gene on incretin hormones. In fact, its results show something else entirely.

What the researchers did here was take eight subjects with the specific variant of the TCF7L2 gene that has been linked to Type 2 diabetes and compare them to a group of 10 controls lacking this gene variant. The tool used was a fancy 5 hour glucose tolerance test. (Yes, I know this is a pitifully small sample which makes its result suspect, and thanks for noticing.)

As described in the study the subjects:
underwent 5-h oral glucose tolerance test (OGTT), isoglycemic intravenous glucose infusion, and graded glucose infusion (GGI).
The isoglycemic infusion is one where glucose levels are maintained at a constant level. In the graded glucose infusion the glucose amount is raised in steps in amounts that are usually calculated as a function of the subject's body weight. This is because glucose raises blood sugar in inverse proportion to the subject's body weight: the more a person weighs, the less rise there is with each additional gram of glucose.

Note that the researchers made no direct measurement of the incretin hormones, GLP-1 and GIP in the course of the study. They drew their conclusions about incretin hormones after applying a mathematical model to the glucose tolerance test results.

As stated in the study:
The incretin effect was assessed from ratios of the insulin secretory rates (ISR) during oral and isoglycemic glucose infusions.
This strikes me as an odd way to determine the effect of incretin hormones. I'm sure the model was based on the findings of some other study, but without direct measurement of the incretin hormones the conclusion has to be labeled, at best, "speculative".

So let's ignore that for now, and see what we can safely conclude from this fancy glucose tolerance test. And it turns out that it is something worth noting. The study found that
β-cell responsivity to oral glucose was 50% lower (47 ± 4 vs. 95 ± 15 × 109 min−1; P = 0.01) in the group of subjects with risk-conferring TCF7L2 genotypes compared with control subjects.
This means the TCF7L2 gene carried by so many people with Type 2 diabetes damages the ability of the beta cell to secrete insulin in response to rising blood sugars.

If so, we can define TCF7L2-related Type 2 Diabetes as a disease of insulin insufficiency, NOT, as we are usually told, a disease caused by insulin resistance.

The headlined conclusion of this study, based on the estimates of "incretin effect" derived from the mathematical model is that:
The TCF7L2 variant rs7903146 appears to affect risk of type 2 diabetes, at least in part, by modifying the effect of incretins on insulin secretion. This is not due to reduced secretion of GLP-1 and GIP but rather due to the effect of TCF7L2 on the sensitivity of the β-cell to incretins.
This translates into saying that normal amounts of incretin hormones are being made, but the beta cell isn't responding to them. Given that this conclusion is drawn without any measuring of incretin hormone levels, the only part of this statement that is reliable is the "at least in part" which translates into, "Perhaps, maybe."

In any case, this is not the first study to find that the common genes associated with Type 2 Diabetes cause failure to secrete insulin, NOT insulin resistance. The more research done into these genes, the more the balance is shifting to finding that Type 2 Diabetes is often an insulin deficiency disease.

You can read about the research that had identified the common Type 2 Diabetes genes in this excellent summary:

NIH News: Newly Identified Genes Influence Insulin and Glucose Regulation: Five of these variants raise type 2 diabetes risk.

Note this extremely interesting statement from the lead researcher in this large scale effort to find Type 2 Diabetes genes:
"The hallmarks of type 2 diabetes are insulin resistance and impaired beta cell function. We were intrigued to find that most of the newly found variants influence insulin secretion rather than insulin resistance. Only one variant, near IGF1, is associated with insulin resistance," said lead author Inês Barroso, Ph.D., of the Wellcome Trust Sanger Institute, Cambridge, England.
You can read about much more research that links Type 2 Diabetes to genetic flaws both inherited and caused by environmental pollutants on the web page,

You Did Not Eat Your Way to Diabetes.

If you have been blaming yourself for causing your diabetes, I urge you to take a look at that page. You'll feel a lot better about yourself after you do.

 

February 9, 2010

Inflammation Raises Blood Sugar

Many people diagnosed with Type 2 diabetes are not aware that the presence of significant inflammation anywhere in the body can raise their blood sugar. But this is a very important finding. In rare cases, people can lower their blood sugar significantly by eliminating the inflammation.

Unfortunately, because high blood sugar weakens the immune system, diabetes can create a vicious circle where inflammation raises blood sugar which deactivates the immune system components that should fight the inflammation, allowing the inflammation to increase, and further raising blood sugar.

A very common site for inflammation that can have this kind of effect is the gum. Dr. Richard K. Bernstein, author of Dr. Bernstein's Diabetes Solution: The Complete Guide to Achieving Normal Blood Sugars has long preached about the importance of eliminating the infection associated with gum disease.

The usual way dentists approach treating gum disease is to treat it with antibacteria mouthwashes and gum surgeries until, inevitably, the teeth all have to be removed. Dr. Bernstein suggests treating it with a long-term aggressive course of antibiotic therapy. This is controversial because of the side effects of long term antibiotic use, but he reports that this approach is successful and lowers his patients' blood sugars. He doesn't comment on whether it allows them to keep their teeth, which would be worth knowing.

A meta study published in this month's edition of the journal, Diabetes Care reviewed the research on the relationship between periodontal treatment and A1c and concluded that such treatment appeared to lower the A1c. Unfortunately, because this is a meta study, the definition of "periodontal treatment" is different from study to study, which limits its usefulness and keeps the metastudy's finding from being "robust."

You can see that study here:

Effect of Periodontal Treatment on Glycemic Control of Diabetic Patients: A systematic review and meta-analysis. Wijnand J. Teeuw et al. Diabetes Care February 2010 vol. 33 no. 2 421-427. doi: 10.2337/dc09-1378

It is worth noting that other studies have linked the presence of gum disease with the development of heart disease. This association may or may not be independent fact that blood sugars in the "prediabetic range" also raise the risk of heart disease. The incidence of heart disease increases dramatically as blood sugars rise into the "pre-diabetic" range and hit 155 mg/dl (8.6 mmol/L) one hour after glucose challenge. (I blogged about the study documenting that HERE.) It is not known whether eliminating the bacteria associated with gum disease after it has occured lowers the risk of heart disease.

Smoking greatly increases the incidence of gum disease, by damaging the tiny capillaries that should bring immune system cells to the gum where they can fight off the infections. This may have something to do with why smoking increases the risk of heart attack.

Gum disease is only one kind of inflammation that can raise blood sugar. Systemic autoimmune inflammatory conditions like Rheumatoid Arthritis and Lupus can also have an impact on blood sugar and I have received anecdotal reports from people who have found dietary ways of controlling their RA which also lowered their blood sugar.

It is possible that the inflammatory effect of gluten on many people who have forms of celiac disease may explain why the elimination of grains from the diet has such a powerful effect on the blood sugar of some people with diabetes beyond the fact that cutting out grains lowers carbohydrates.

There is some evidence that obesity may be associated with an inflammatory state in the fat cells. You can read a summary of research on this topic HERE.

I am not certain that the obesity is causing this inflammation, however, since I know for a fact that in Type 2 Diabetes, the elevated blood sugar or abnormal level of genetically caused insulin resistance is present long before the individual becomes obese. It is quite possible that in humans the inflammation of fat cells precedes the development of obesity. Inflammation may do this by damaging the receptors the fat cells use to take in the circulating peptides the body uses to regulate fat storage and fat burning.

Another area of the body that is prone to low level inflammation that is very difficult to diagnose and treat is the urinary tract. Because the urine of people with diabetes can be full of glucose which feeds invasive bacteria, people with diabetes are very prone to get urinary tract infections.

Unfortunately, the bacteria that cause these infections form bacterial mats which can make these infections very difficult to eliminate. The antibiotics given for urinary tract infections tend to knock back the bacteria rather than eliminate them and over time repeat antibiotic use can breed drug resistant superbugs.

Even worse, these bacterial mats may keep bacteria bound up and prevent them from showing up in cultures in numbers high enough to provide a diagnosis. This is particularly true when the bacteria have colonized the urethrea.

If you have an ongoing problem with recurring urethral symptoms that don't culture, do not jump to the conclusion that you have a non-infectious condition such as Interstitial Cystitis, until you have tried several long term treatments with powerful antibiotics that are known to reach the urethra. Not all drugs routinely prescribed for urinary tract infection reach the urethra. Macrodantin (nitrofurantoin) does not.

One area where treating inflammation may worsen insulin resistance is heart disease. We know now that statins have a positive effect on the subset of people elevated cardiac-specific C Reactive Protein (CRP), which is an index to inflammation in the blood vessels. This effect appears to have little to do with the fact these drugs lower LDL cholesterol and everything to do with the fact that they appear to decrease inflammation in the blood vessels.

But statins do not appear to lower insulin resistance in humans, though they might do this in rodents. In fact there is some evidence that statins increase insulin resistance in humans. I have blogged about that finding HERE.

 

February 3, 2010

The Lancet Study: Old Patients Victimized By Poor Treatment Die of Hypos from 70/30 Insulin Regimens

The latest outrage perpetrated on the diabetes community is a study published recently in the Lancet which is being widely reported in the media as proving that the 6.5% A1c is dangerous and that the "safest" A1c for people with diabetes is one of 7.5%.

The 7.5% A1c corresponds to an average blood sugar of 169 mg/dl (9.4 mmol/L). To get an average that high a person would typically be seeing blood sugars rising into the middle 200s after every meal, a level that the ADA has confirmed is associated with the development of retinopathy and eventually, blindness. That A1c also guarantees you will develop neuropathy. Two previous studies, ACCORD and ADVANCE both found that lowering A1c to 6.5 lowered neuropathy significantly.

The abstract of this study can be found here:

Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Dr Craig J Currie. The Lancet, Early Online Publication, 27 January 2010. doi:10.1016/S0140-6736(09)61969-3

Unfortunately, this study can only be understood by reading the full text which is NOT available for free. Someone sent me a copy so I was able to read it, and I will summarize the most important points that the full text makes for you. Save them off somewhere, because it is almost certain your doctor, who does not have access to the full text will NOT understand the conclusions of this study and will use it to deny you the treatment you need to keep your A1c in the low, safe zone that will prevent you from getting complications.

I am going to keep this brief to make it easy for you to grasp the concepts you will need to know to counter the arguments your doctor might make.

1. WHO WAS STUDIED: This Study analyzed records of about 50,000 British Patients Dating Back to 1986. In this study there were two and a half times as many patients with A1cs of near 11% as there were patients with A1cs near 7%. This reflects the abysmal treatment patients in the UK received during this period which was characterized by treatment that let them maintain very high A1cs for years before being offered insulin.

The average age of the patients with 11% A1cs was 59.7. The average age of those with the lowest A1cs was 67.4. This again reflects the fact that people in the UK had to spend years with very high blood sugars before being given insulin to lower blood sugars. The study methodology suggests very strongly that these people with 6.5% A1cs had low A1cs because they had been put on insulin, and that they had been put on insulin only after experiencing years of extremely high A1cs.

One reason for these very high blood sugars is that British patients, even today, are usually not given blood sugar meters until they have had uncontrolled diabetes for long enough to produce serious complications. They are never told that they can lower their blood sugars by cutting back on carbohydrates. Instead they are told to cut back on fat with the implication that fat is what raises their blood sugars.

Most of the patients in this study were not diagnosed with until their fasting blood sugar was 140 mg/dl (7.7 mmol/L) as this was the diagnostic standard until 1998. The Hoorn Study showed that fully half of all people diagnosed with this fasting blood sugar cut off already have significant neuropathy on the day of diagnosis. This means they probably had undiagnosed diabetes--post- meal blood sugars over 200 mg/dl (11 mmol/L) for as long as a decade before diagnosis.

The patients who'd been put on intensive therapy already had 2.5 times much severe diabetic kidney damage diagnosed by high creatinine levels as did the younger patients. Keep in mind that the younger patients also had the very high A1cs guaranteed to give them kidney problems as they grew older.

CONCLUSION: The people with low A1cs in this study were those who had spent many years with damagingly high blood sugars, both before and after diagnosis. Many had spent nearly a decade with A1cs near 11%. They were not put on insulin until they had already developed serious diabetic complications.

2. HOW WERE THEY TREATED: The patients given oral treatment were all given sulfonylurea drugs. Since this study goes back to the 1980s, this means they were given the first generation sulfonylurea drugs--the ones now known to promote heart attack. There is a black box warning on all sulfonylurea drugs in the US because of their proven association with increased heart attack death.

The full text of this study makes it clear that the patients with the 6.5% A1cs were those who had been put on insulin after many years of being out of control.

The study does not break out the kinds of insulin or the regimens used. After reading the diabetes discussion boards for years I can tell you what the typical UK insulin treatment was during the time of this study. It was a 70/30 insulin twice a day. 70/30 insulin is a combination of long acting and short acting insulin, usually in the UK involving NPH as the "long acting" insulin. The fast action portion cannot be matched to carbohydrate intake and NPH is notorious for its unpredictable activity curve and ability to provoke severe hypos.

The 70/30 insulin regimen is the one most likely to cause severe hypos, and from the discussion in this study, that appears to be exactly what it did. The group with the low A1cs had a very high rate of hypo. As stated in the study:
In this study, mortality was three times higher in patients in either the conventional or intensive treatment groups who had severe hypoglycaemia than in those who did not have severe hypoglycaemia.
One factor not discussed in this study is the damage caused by a high degree of blood sugar variation. It is now understood that large fluctuations in blood sugar--for example, a blood sugar that rises from 100 to 300 after a meal and then plunges down to 70 three hours later--are more damaging to tissues than blood sugars that stay stable.

When you give one or two fixed dose shots of 70/30 NPH based insulin to people who are eating high carbohydrate diets you guarantee just that kind of blood sugar variability. The 6.5% A1c will result from a blood sugar that goes high and then drops very low because it is an average.

The Kumamoto Study made it very clear that if A1cs are attained by keeping peaks low rather than going high and then low, far fewer complications result.

Finally, because the people in this study had been out of control for years, they were prone to autonomic neuropathy--damage to the nerves that control the systems the body uses to fight hypo. This made it more likely that if they started to have hypos, they would develope "Hypo unawareness" which causes the severe hypos that damage the brain and body. These are more likely in older Type 2s, which is the group put on the poorly designed insulin regimens used in the UK.

CONCLUSION: The low A1cs in this study were due not to good control but to the dangerous combination of blood sugar highs followed by severe hypos. Both these factors are known to increase mortality.

3. WHAT TO DO IF YOUR DOCTOR URGES YOU TO SHOOT FOR A "SAFE" 7.5 A1C.

Explain that this study is irrelevant to patients who achieve a lower A1c by using a blood sugar meter to monitor their blood sugars and who keep their blood sugar in a narrow normal in a way that does not cause hypos.

Explain that this study is irrelevant to patients diagnosed before they have developed serious complications who avoid sulfonylurea drugs and use modern insulins less likely to provoke hypo.

Explain that doctors who only read one line summaries of studies may inadvertently harm patients. The authors of this study made clear its many limitations, but the reporting of this study even in the medical press is focusing only on its conclusions without citing the many cautions that the authors provided in the text.

Explain to your doctor that there is a large body of research that makes it clear that it is high post meal blood sugars, not A1c that cause neuropathy, retinopathy, and kidney damage, and that you intend to avoid developing any of these horrible complications by maintaining a safe, healthy blood sugar, as measured by blood sugar testing after meals, rather than relying on the A1c test to determine how you are doing.

You are fortunate in that you have read this information here. Sadly most people with diabetes will not, and it is very likely that their doctors will use this irrelevant result to deprive them of the treatment that could prolong their life and prevent them developing life-ruining complications. Insurers love this kind of study too as it justifies them in denying patients expensive care.

 

January 26, 2010

Victoza: A New Competitor for Byetta

The FDA finally approved Novo Nordisk's long delayed GLP-1 analog, Liraglutide, which is marketed under the name, "Victoza."

This drug was developed in the same time frame as Byetta and is similar in concept. But it's side effect profile was more troubling, hence the delay. It's being released with a warning that it might produce thyroid cancers, though this supposedly is mostly a problem in rodents. Even so, the fact that the thyroid cancer issue can't be completely dismissed would make a reasonable person ask, "What does this drug offer that makes it worth taking on even a tiny bit more risk than is found with Byetta?"

You can read the full European prescribing information for Victoza here:

Victoza Prescribing Information.

As far as I can see the only possible benefit to taking Victoza over Byetta is that it requires a once a day shot, rather than the twice a day schedule of Byetta. That said, it appears to produce less blood sugar control than Byetta does--when Byetta works, which isn't always--and reading between the lines, it doesn't look to me as Victoza has as good an impact on weight as Byetta does.

When looking at statistics for both these drugs, keep in mind that other research has found that Byetta is a drug that is worthless for two thirds of of those who take it and magic for the other third. This means that the averages published in Prescribing Information documents aren't a good guide to its effect.

If out of ten people taking a drug, three people drop 30 lbs each and the other seven gain 3 pounds each, the average weight loss is 7 lbs, but that statistic fails to reflect reality in any meaningful way.

The same is true with blood sugar control, as some people respond dramatically to Byetta and others who take it actually see their blood sugar go up.

With this in mind, it's hard to compare Byetta to Victoza based on published statistics. The average A1c drop reported when patients take Victoza and Metformin is 1%, which is really no better than the drop achieved taking Metformin alone.

Most tellingly the Victoza prescribing information presents no statistic for the impact of Victoza on blood sugar when it is not being given in combination with another blood sugar lowering drug.

This suggests very strongly that on average the drug has no impact on A1c, but because it might have a stronger impact on a subset, as Byetta does, it can't be dismissed.

My take on this drug is this: There is little reason to take it. The longer duration means that if you get the serious gastrointestinal reaction that GLP-1 analogs can cause, it's going to take a lot longer to wash out of your body. If you aren't going to respond to Byetta, it isn't likely you'll respond to this drug either, as non-response suggests that fiddling with GLP-1 isn't going to help you. The impact is less than Byetta and the side effects more troubling, especially since it is a new drug and hasn't been prescribed to a large group of patients as Byetta has.

To me the most worrisome side effect is this. As the prescribing information reports,
The overall rates of thyroid adverse events in all intermediate and long-term trials are 33.5 [Victoza], 30.0 [Placebo] and 21.7 events per 1000 subject years of exposure for total liraglutide, placebo and total comparators; 5.4 [Victoza], 2.1 [Placebo] and 0.8 events, respectively concern serious thyroid adverse events. In liraglutide-treated patients, thyroid neoplasms, increased blood calcitonin and goiters are the most frequently thyroid adverse events and were reported in 0.5%, 1% and 0.8% of patients respectively.
Bottom Line: Stick with Byetta and keep an eye on longer-term research findings about this drug. There's no reason to take it that trumps the mediocre performance and possible thyroid risk.

 

January 24, 2010

Keeping it Simple

After years of tracking diabetes news, we old-timers can become jaded. We've seen hundreds of mouse "cures" that go nowhere, hundreds of poorly designed studies meant to promote some product or scientific-religious belief, and very few new ideas that are worth the time it takes to find them. When we turn to a blog like this, we want to read something new, and when we write a blog like this, we may think that if we don't have something exciting to report, we probably should shut up.

But when I look at my blog and web site stats to see what people are reading here, and when I reflect on the many emails I get from site visitors, it's crystal clear that what excites the majority of the visitors to my blog and the main Blood Sugar 101 web site is not the fascinating new tidbits I occasionally dig up--the ones that interest the devoted core of readers who are likely to post comments on the blog.

What attracts and generates responses from those visitors is the simple stuff that is so obvious to us old-timers we find it boring--the stuff that, sadly, 98% of all people with Diabetes world wide don't yet know.

Based on my mail and stats, here's the information that amazes people about the blog and site:

1. Normal blood sugars are much lower than the targets doctors tell patients to shoot for.

2. Diabetic blood sugars can be improved dramatically and even, for some people normalized, by cutting back on the carbs we eat.

3. Some diabetes drugs are safer and more effective than others but doctor often do not understand how to use diabetes drugs appropriately. With both metformin and insulin they often prescribes doses that are too low to do any good. By the same token, most if not all supplements sold as being "good for diabetics" are a complete waste of money.

4. Testing after meals is the best way to find out what foods are a good diabetes diet for you. Each person's diabetes is different, and without testing your favorite meals you won't know what foods are raising your blood sugar to levels that damage your body.

5. The so-called glycemic index doesn't work for most people with diabetes. Grains, whole or not, raise blood sugar dramatically.

6. Many people with Type 2 diabetes can drop their blood sugars surprisingly quickly without having to lose a single pound just by cutting down on carbs. Conversely, contrary to what doctors tell us, people with diabetes can lose a lot of weight and not see underlying blood sugar control improve. This is because most people with Type 2 have defects in insulin secretion that will not go away no matter what they weigh.

7. If you are thin and over 30 and diagnosed with "Type 2 Diabetes" and don't respond to pills there is good a chance you have either a slow form of autoimmune diabetes or, far more rarely, one of the genetic syndromes lumped together under the label "MODY." If so, you need to see a competent endocrinologist who is aware of these newer diagnoses. Unfortunately, not all practicing endocrinologists keep up-to-date.

There's nothing dramatically new here. It's all things I'd learned by 2003 after reading the diabetes newsgroup every day for a year. The new research that has trickled in since then has added very little that is new. Mostly it has confirmed that it's safe to cut carbs, a bad idea to eat low fat diets, and that there are more people with oddball forms of diabetes in the population than used to be thought.

So it strikes me that we in the blogosphere need to keep in mind, that yes, it's fascinating to read about obscure research that points to this or that possibly useful micro-finding. It's good there are bloggers out there tracking it, and I'm going to keep scanning the journals myself.

But when we are writing for a Googling world audience, it's far more important to keep the focus on the simple, boring facts about how blood sugar works that most people with diabetes still don't know. That knowledge is what can keep people from going blind, losing kidneys, or ended up with amputations.

I love my highly knowledgeable fans who read every post and keep up with the research cites. But I love even more the people who write to me that they've had diabetes for five years, but only brought their A1c down from 9% to 5.6% this past month after trying out the technique they found HERE. Even more, I love the people who write me two years later that they're still using that technique and still getting A1cs in the 5% range.

That's what matters. So if you've become bored with hearing about the "same old, same old" stuff, remind yourself it's not old stuff to the majority of people diagnosed with Type 2 diabetes whose average A1c is up near 9% and whose doctors have little to suggest even when their fasting blood sugar is up near 200 mg/dl.